Clinical and Biological Remission With Tezepelumab: The Real‐World Response in Severe Uncontrolled Asthma
Tezepelumab led to substantial clinical improvements and clinical remission in up to 55% of T2-high patients with severe asthma. A disconnect between clinical and biological remission was observed. The long-term significance of residual T2 inflammation on tezepelumab is unknown.
Authors
- Jessica Gates (ORCID: https://orcid.org/0000-0002-7777-0201)
- Jaideep Dhariwal (ORCID: https://orcid.org/0000-0003-2352-5638)
- F Haris
- Mariana Fernandes (ORCID: https://orcid.org/0000-0002-7005-2805)
- Francesca Cefaloni (ORCID: https://orcid.org/0009-0004-6929-0912)
- Paniz Khooshemehri
- Cris Roxas
- J Lam
- David J. Jackson (ORCID: https://orcid.org/0000-0002-2299-868X)
- G d’Ancona (ORCID: https://orcid.org/0000-0003-1936-6769)
- Louise Thomson (ORCID: https://orcid.org/0000-0001-7492-7827)
- Alexandra M. Nanzer (ORCID: https://orcid.org/0000-0002-7928-6317)
- Linda K. Green (ORCID: https://orcid.org/0000-0003-2499-8816)
Institutions
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
Publication Details
- Journal
- Allergy
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1111/all.16590
- Citations
- 21
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 24.45